Forever Labs was founded by a group of biomedical research scientists and medical doctors with the goal of helping everyone live longer, healthier lives.
Chief Executive Officer
Prior to Forever Labs, Steven Clausnitzer spent 15 years mentoring and developing top-talent at fortune 500 companies including American Express and Wolters Kluwer. Steven has extensive experience in strategic growth, commercialization, and team leadership.
Mark Katakowski, PhD
Mark Katakowski received a B.S. in Physics and a Ph.D. in Medical Physics from Oakland University. He has over 15 years experience investigating bone mesenchymal stem cell (MSC) therapies for neurological disease, and an extensive scientific publication record. Dr. Katakowski was first to demonstrate that microRNA functions as an intercellular communication molecule between brain tumor cells. This work led to his finding that bone marrow MSCs communicate with the nervous system via blood-born exosomes. Dr. Katakowski's hypothesis that bone marrow cell degradation contributes to aging and age-related disease is the founding principle of Forever Labs.
Chief science Officer
Benjamin Buller, PhD
Benjamin Buller received his B.S.E. in Mechanical Engineering and Ph.D. in Medical Physics from Oakland University, and has over 10 years experience in stem cell therapies for neurological and age-related disease. He has spent his career investigating the mechanisms by which bone marrow mesenchymal stem cells (MSCs) enhance recovery after neural injuries and stroke. Dr. Buller has pioneered the use of MSC exosomes for treatment of stroke and cortical injury, and is the first person to use MSC exosomes to treat non-human primates after neural injuries, work that is advancing to clinical trials. Dr. Buller's collaborations with Dr. Katakowski have led to numerous IP filings for novel treatments of neurologic disease.
Chief Medical Officer
Laith Farjo, MD
Laith Farjo received his medical degree from University of Michigan in 1993, and completed his internship in general surgery and residency in orthopedic surgery from University of California, San Francisco. Dr. Farjo is a specialist in advanced arthroscopic surgery, and has developed novel techniques and patented procedures that allow for quicker procedures and reduced recovery time. Dr. Farjo became interested in stem cells via his routine deployment of bone marrow concentrate to help patients avoid or heal quicker from surgery. He has served as CEO of several ventures, co-founded a medical brace company, and is a leader in local business development. Dr. Farjo has received numerous national and local awards, including being honored as an Hour Detroit Magazine's Top Doctor from 2012-2016.
Chief Technology Officer
Michael Elfassy, MBA, B.Eng
Michael Elfassy has a B.Eng in Computer Engineering from McGill and a M.B.A. from HEC Montreal. Michael is a full-stack developer, and has over 10 years experience building state-of-the-art online applications.
Chief Management Officer
Edward Cibor is an expert in regulation and staffing, with over 10 years experience as a compliance officer and project manager executing IT projects for clients ranging from General Motors to USA TACOM Life Cycle Management Command.
At Forever Labs, our goal is good health for everyone. We believe that science, human ingenuity, and the fortune of having been born at a time when all things seem possible, have given us a unique opportunity to improve the human condition. As we pursue this purpose, the following principles serve as pillars in our day-to-day function.
First, we honor every customer’s trust in Forever Labs. They are the heart of our business. In return for that trust, we deliver the highest level of service and the highest quality of care for their irreplaceable stem cells. They receive no less than our full effort in return for their investment.
Second, we honor the work of the physicians who perform our procedures. If our customers are the heart of Forever Labs, then these medical practitioners are our limbs. Their role is indispensable, and we serve their needs as attentively as those of our customers. To grow and thrive, we rely upon these gifted physicians, and as we do so, we deliver to an equally high standard.
Third, we maintain the highest level of scientific integrity. We apply the most current developments in science with a comprehensive and discerning eye. We keep our customers informed as these advancements in stem cell therapy increase the value of their cellular assets. We are the eyes and ears for our customers, always keeping them aware of developments in this cutting-edge field as they unfold.